Press Releases - 2025-06-26
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
Press Releases - 2025-05-20
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
Press Releases - 2025-05-09
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
Press Releases - 2025-05-01
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
Press Releases - 2025-04-30
PureTech Announces Annual Results for Year Ended December 31, 2024
